Business Intelligence on Biologic and Small Molecule Drugs
Figure 2. Erdos interactome representations of drugs
Figure 2. Erdos interactome representations of drugs. Many drugs developed for a given indication usually share a common core motif. Substitutions are made on this core scaffold to tune the biological and drug-like properties and generate intellectual property. An Erdos interactome representation for drugs available or designed to treat a particular disease can be built with the drugs closest to the center sharing that core. More distant members in this interactome will more than likely have different cores. At the farthest reaches of this interactome, members might find use in other disease as their structures (green arrows) might resemble or completely overlap with
drugs designed for other indications. (A) Part of the receptor tyrosine kinase inhibitors interactome centered around a quinazoline core. (B) Part of the angiotensin converting enzyme inhibitors interactome centered around an aminopropanamido-propanoic acid core. (C) Part of the beta blockers interactome centered around an isopropylamino-propan-2-ol core.
Figure 2. Erdos interactome representations of drugs. Many drugs developed for a given indication usually share a common core motif. Substitutions are made on this core scaffold to tune the biological and drug-like properties and generate intellectual property. An Erdos interactome representation for drugs available or designed to treat a particular disease can be built with the drugs closest to the center sharing that core. More distant members in this interactome will more than likely have different cores. At the farthest reaches of this interactome, members might find use in other disease as their structures (green arrows) might resemble or completely overlap with
drugs designed for other indications. (A) Part of the receptor tyrosine kinase inhibitors interactome centered around a quinazoline core. (B) Part of the angiotensin converting enzyme inhibitors interactome centered around an aminopropanamido-propanoic acid core. (C) Part of the beta blockers interactome centered around an isopropylamino-propan-2-ol core.